18F-氟昔洛韦与PSMA PET在初诊高危前列腺癌原发肿瘤检测中的比较:系统综述与荟萃分析
该系统综述与荟萃分析比较18F-氟昔洛韦与PSMA PET在高危前列腺癌初始分期中原发肿瘤检测的诊断准确性,共纳入17项研究(18F-氟昔洛韦4项、PSMA 13项),汇总敏感度、特异度及诊断比值比均无统计学显著差异。
要点
- 18F-氟昔洛韦与PSMA PET在高危前列腺癌原发肿瘤检测中的诊断准确性无统计学显著差异。
- 汇总敏感度:18F-氟昔洛韦85% vs PSMA 84%(P = .78)。
- 汇总特异度:18F-氟昔洛韦77% vs PSMA 83%(P = .40)。
核心结论
- 18F-氟昔洛韦与PSMA PET在高危前列腺癌初始分期原发肿瘤检测中的诊断准确性无统计学显著差异。
研究设计与样本
- 系统综述与荟萃分析,检索2012年至2020年发表的原创研究,纳入28项符合标准的研究,其中17项纳入荟萃分析(18F-氟昔洛韦4项、PSMA 13项),以组织病理学结果为参考标准,采用QUADAS-2工具进行质量评价,使用随机效应模型汇总效应量。
诊断标准与关键数值
- 18F-氟昔洛韦 vs PSMA的汇总敏感度85%(95% CI:73%,92%)vs 84%(95% CI:77%,89%)(P = .78);汇总特异度77%(95% CI:60%,88%)vs 83%(95% CI:76%,89%)(P = .40);汇总诊断比值比18.88(95% CI:5.01,71.20)vs 29.37(95% CI:13.35,64.60)(P = .57)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 17项研究中有12项(70%)在某一评价领域被判定为高偏倚风险。
- 9项研究被认为存在适用性担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose Fluorine 18 (18F)-fluciclovine and prostate-specific membrane antigen (PSMA) tracers are commonly used for localizing biochemical recurrence of prostate cancer, but their accuracy in primary tumor detection in the initial staging of high-risk prostate cancer has not been established. Materials and Methods A systematic review was performed of the electronic databases for original studies published between 2012 and 2020. Included studies were those in which 18F-fluciclovine or PSMA PET was used for initial staging of patients with high-risk prostate cancer. The diagnostic performance data were collected for primary tumor with histopathologic results as reference standard. The Quality Assessment of Diagnostic Accuracy Studies-2 tool was used for quality appraisal. A random-effects model was used to summarize the effect sizes and to evaluate the difference between two groups. Results Overall, 28 studies met the eligibility criteria, and 17 were included in the meta-analysis (18F-fluciclovine = 4, PSMA = 13). Of these 17 studies, 12 (70%) were judged to have high risk of bias in one of the evaluated domains, and nine studies were deemed to have applicability concerns. The pooled sensitivity, specificity, and diagnostic odds ratio for 18F-fluciclovine versus PSMA were 85% (95% CI: 73%, 92%) versus 84% (95% CI: 77%, 89%) (P = .78), 77% (95% CI: 60%, 88%) versus 83% (95% CI: 76%, 89%) (P = .40), and 18.88 (95% CI: 5.01, 71.20) versus 29.37 (95% CI: 13.35, 64.60) (P = .57), respectively, with no significant difference in diagnostic test accuracy. Conclusion 18F-fluciclovine and PSMA PET demonstrated no statistically significant difference in diagnostic accuracy in primary tumor detection during initial staging of high-risk prostate cancer. Keywords: PET, Prostate, Molecular Imaging-Cancer, Staging Supplemental material is available for this article. © RSNA, 2022.
引用
- Yadav D, Hwang H, Qiao W, et al. 18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer. 2022. PMID: 35212559. doi:10.1148/rycan.210091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。